<DOC>
	<DOCNO>NCT03105141</DOCNO>
	<brief_summary>This prospective , randomize , single-center clinical trial design figure optimal algorithm remote ischemic conditioning patient chronic cerebral ischemia .</brief_summary>
	<brief_title>Optimized Remote Ischemic Conditioning ( RIC ) Treatment Patients With Chronic Cerebal Ischemia</brief_title>
	<detailed_description>Chronic cerebral ischemia ( CCI ) refers prevalent pathophysiological condition cerebral hypoperfusion cause reduction cerebral blood flow long period time . CCI , consequence intracranial atherosclerotic stenosis ( ICAS ) identify one major culprit responsible occurrence/recurrence acute cerebrovascular accident ischemic stroke transient ischemic attack , well vascular cognitive dysfunction . The prevalence ICAS related CCI among stroke patient remarkably high Chinese population white , quite effective therapy general patient population ICAS . Endovascular intervention appear promising option group patient severe ICAS , may applicable certain vascular risk feature suppose increase rate complication result unsatisfactory clinical outcome . In addition , high cost adverse effect medication pose huge burden patient , family even whole society well . RIC novel therapeutic approach whereby repetitive , transient , non-lethal ischemia intervene reperfusion employ distant organ tissue confers protection target organ subsequent major ischemic attack . Preclinical experimental study demonstrate neuroprotective effect RIC ischemic stroke model . Meanwhile , small-scale , proof concept clinical trial reveal long-term RIC able low stroke recurrence enhance cerebral reperfusion , without induce adverse event patient ICAS . Nevertheless , current protocol RIC utilited scenario mainly base previous animal study cardiovascular clinical trial . Whether modify ischemic pressure , number cycle , duration ischemia well method application lead different outcome remain settled . In study , 600 patient satisfied inclusion criterion recruit randomly allocate four substudies receive RIC treatment ( Doctormate® ) different algorithm . The optimal algorithm RIC patient ICAS related CCI would determine accord clinical endpoint . Other medical management guarantee base best medical judgment clinical practitioner .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Intracranial Arteriosclerosis</mesh_term>
	<criteria>1 . Age range 45 80 year age , gender ; 2 . Patients diagnose ischemic stroke TIA admission follow requirement satisfy well : 1 . The occurrence ischemic stroke within 30 day baseline modify Rankin Scale ( mRS ) score≤4 . 2 . The occurrence TIA within 15 day baseline Oxfordshire Community Stroke Project basis age , blood pressure ( BP ) , clinical feature , duration TIA symptom ( ABCD2 ) score≥4 . 3 . Patients symptomatic intracranial atherosclerotic stenosis ( sIAS ) attribute least 50 % stenosis diameter major intracranial artery ( carotid artery , middle cerebral artery ( M1 ) ) verify magnetic resonance angiography ( MRA ) compute tomographic angiography ( CTA ) . 4 . Informed consent obtain patient health care proxy , appropriate , able cooperate participate followup visit . 1 . Received intravenous intraarterial thrombolytic therapy recombinant tissue plasminogen activator ( rtPA ) within 24 hour prior inclusion . 2 . Progressive deterioration neurological manifestation within 24 hour prior inclusion . 3 . Intracranial arterial stenosis due follow nonatherosclerotic etiology , instance , moyamoya disease , artery dissection , know vasculitic disease , intracranial infection , radiation induce vasculopathy , cerebrospinal fluid ( CSF ) pleocytosis associate intraarterial stenosis , genetic developmental abnormality fibromuscular dysplasia , neurofibromatosis , sickle cell disease , mitochondrial encephalopathy , intracranial granulomatous arteritis , postpartum angiopathy , suspect vasospasm embolism , iatrogenic trauma . 4 . Intracranial abnormality tumor , abscess , vascular malformation , cerebral venous sinus stenosis thrombosis . 5 . Any hemorrhagic transformation large area cerebral infarction ( 1/3 middle cerebral artery perfusion territory ) . 6 . Any type intracranial hemorrhage within 90 day prior inclusion . 7 . Potential cardiac source embolism rheumatic mitral aortic stenosis , prosthetic heart valve , atrial flutter , atrial fibrillation , leave atrial myxoma , sick sinus syndrome , patent foramen ovale , leave ventricular mural thrombus valvular vegetation , congestive heart failure , bacterial endocarditis . 8 . Previous stent , angioplasty , mechanical device target lesion , plan receive procedure within 12 month inclusion . 9 . Refractory hypertension ( systolic blood pressure ( SBP ) &gt; 180 mmHg ; diastolic blood pressure ( DBP ) &gt; 110 mmHg ) control medical intervention . 10 . Above 50 % stenosis extracranial artery ( carotid artery vertebral artery ) 11 . Above 50 % stenosis subclavian artery subclavian steal syndrome . 12 . Retinal hemorrhage visceral bleeding within 30 day prior inclusion . 13 . Myocardial infarction within previous 30 day prior inclusion . 14 . Previous history major surgery within 30 day prior inclusion , arranged procedure within 12 month inclusion . 15 . Severe hemostatic coagulation disorder ( Haemoglobin &lt; 10 g/dL , blood platelet count &lt; 100 × 109/L ) 16 . Hepatic renal dysfunction ( aspartate transaminase ( AST ) and/or alanine transaminase ( ALT ) &gt; 3×upper limit normal range , creatinine clearance &lt; 0.6 ml/s and/or serum creatinine &gt; 265 μmol/l ( &gt; 3.0 mg/dl ) ) . 17 . Current history chronic physical disease mental disorder . 18 . Life expectancy &lt; 3 year due concomitant lifethreatening illness . 19 . Contraindications remote ischemic conditioning : significant peripheral arterial disease , soft tissue vascular injury , wound , fracture affect upper limb . 20 . Pregnant lactating woman . 21 . Patients unlikely compliant intervention return followup visit . 22 . No consent obtain patient available legally authorize representative . 23 . Patients recruit another clinical investigation medication device , likely impact outcome study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Intracranial atherosclerotic stenosis</keyword>
	<keyword>Remote ischemic conditioning</keyword>
	<keyword>Stroke</keyword>
</DOC>